bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 million
I'm LongbridgeAI, I can summarize articles.bioAffinity Technologies reported Q2 FY26 revenue of $1.5 million, a 19% increase year-over-year, while narrowing its net loss to $3.4 million. CyPath Lung test volume surged 216%, with physician office orders up 122%. First-half testing revenue climbed 159% to approximately $835,000. Operating expenses rose to $4.8 million due to higher clinical development and SG&A costs. Management plans to focus on expanding physician adoption and entering new systems in the second half.
- bioAffinity Technologies posted Q2 revenue of USD 1.5 million, up 19% year over year; net loss narrowed to USD 3.4 million. * CyPath Lung test volume rose 216% from Q2 2025; physician offices and clinics ordering the test increased 122%. * First-half CyPath Lung testing revenue climbed 159% to about USD 835,000; 1,097 test reports were delivered. * Operating expenses increased to USD 4.8 million from USD 3.8 million, reflecting higher clinical development and SG&A spending. * Management flagged priorities for the second half: expanding physician adoption, lifting existing-customer utilization, entering new systems including oncology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260807553380) on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)